Quent Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Quent Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-796	Closed	-$19K	–	1159
2022 Q1	$19K	Hold	796	–	–	﹤0.01%	796
2021 Q4	$19K	Buy	+796	New	+$16K	﹤0.01%	724

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quent Capital's ACAD Position: Q2 2022 in Review

Quent Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 796 shares — an estimated $19K sold.

Quent Capital first reported a position in ACAD in Q4 2021 and held it in 2 quarters. The position peaked at $19K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

Quent Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Quent Capital sold 796 Acadia Pharmaceuticals shares in Q2 2022, an estimated $19K.
Quent Capital first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Quent Capital's Acadia Pharmaceuticals position peaked at $19K in Q1 2022.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Quent Capital's 13F filing for Q2 2022, filed 8 Aug 2022.